Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant

StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv6
  2. Lead sponsor: University of Nebraska to University of Oklahoma
    • Primary and study completion dates changed from estimate of Mar 2010 to Jan 2011
    • Trial status: Active, Not Recruiting to Completed
    • Enrollment target: estimated 20 to confirmed 16
    v5
  3. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Mar 2010
    • Study completion date: Dec 2008 to Mar 2010
    • Site details revised
    v4
  4. Study arms: 0 to 1v3
  5. Primary endpoints: 4 to 1
    • Eligibility criteria revised
    • Secondary endpoints expanded, about 66 words
    • Study description revised
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Oklahoma
162 trials monitored
See 7 trials at risk
Diabetes
5,141 trials monitored
See 246 trials at risk
Type 2 Diabetes
2,257 trials monitored
See 120 trials at risk
This study is designed to look at the effect sitagliptin has on tacrolimus and sirolimus drug levels in kidney transplant patients. It is also designed to look at the side effects experienced in the transplant population.
Trial Details
NCT Number NCT00466518
Lead Sponsor University of Oklahoma
Conditions
(from sponsor)		 Kidney Transplant, Type 2 Diabetes
Related terms Diabetes Mellitus, Type 2
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov